Limits...
In a safety net population HPV4 vaccine adherence worsens as BMI increases.

Harper DM, Else BM, Bartley MJ, Arey AM, Barnett AL, Rosemergey BE, Paynter CA, Verdenius I, Harper SM, Harris GD, Groner JA, Malnar GJ, Wall J, Bonham AJ - PLoS ONE (2014)

Bottom Line: Females with normal BMI received on-time triplet dosing significantly more often than did the obese class II and III females (30% vs. 18%, p<0.001).Pregnancy history has a significant influence on BMI and HPV4 dosing compliance in this safety net population where 71% had been gravid.Obesity, as well as gravidity and Hispanic race, are risk factors for lack of HPV4 vaccine adherence among young females in a safety net population.

View Article: PubMed Central - PubMed

Affiliation: Department of Community and Family Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, United States of America; Department of Obstetrics and Gynecology, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, United States of America; Department of Biomedical and Health Informatics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, United States of America.

ABSTRACT

Objectives: Obesity adversely inhibits antibody response to vaccination. Three doses of HPV4 may or may not provide adequate long term protection against HPV 16/18 in obese females. The aim of this study was to determine whether adherence to HPV4 vaccination in a safety net population was reduced with increasing body mass index (BMI).

Methods: We designed a historical prospective study evaluating the number and dates of HPV4 dosing that occurred from July 1, 2006 through October 1, 2009 by the demographic characteristics of the 10-26 year old recipient females. The defined dosing intervals were adapted from the literature and obesity categories were defined by the WHO.

Results: 1240 females with BMI measurements received at least one dose of HPV4; 38% were obese (class I, II and III) and 25% were overweight. Females with normal BMI received on-time triplet dosing significantly more often than did the obese class II and III females (30% vs. 18%, p<0.001). Obese class II/III females have a significant 45% less chance of completing the on-time triplet HPV4 series than normal women (OR = 0.55, 95% CI: 0.37, 0.83). Pregnancy history has a significant influence on BMI and HPV4 dosing compliance in this safety net population where 71% had been gravid. Hispanic females were less likely to complete HPV4 dosing regardless of BMI (aOR = 0.39, 95% CI: 0.16, 0.95).

Conclusions: Obesity, as well as gravidity and Hispanic race, are risk factors for lack of HPV4 vaccine adherence among young females in a safety net population.

Show MeSH

Related in: MedlinePlus

Distribution of mistimed triplet HPV4 dosing by BMI category.Among women receiving three doses of HPV4, obese III women received at least one early dose among the triplet series significantly more often than normal women (25% vs. 13%, p<0.001); and at least one late dose among the triplet series significantly less often than normal women (23% vs. 17%, p<0.001).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4116139&req=5

pone-0103172-g002: Distribution of mistimed triplet HPV4 dosing by BMI category.Among women receiving three doses of HPV4, obese III women received at least one early dose among the triplet series significantly more often than normal women (25% vs. 13%, p<0.001); and at least one late dose among the triplet series significantly less often than normal women (23% vs. 17%, p<0.001).

Mentions: 64% of obese II/III women received three HPV4 doses on time with 36% mistiming at least one dose. Figure 2 shows that obese II/III women received at least one early or late dose equally often (22% vs. 16%, p>0.05), whereas normal BMI women received late doses more often than early doses (23% vs. 13%, p<0.5). Among women receiving three doses of HPV4, obese III women received at least one early dose among the triplet series significantly more often than normal women (25% vs. 13%, p<0.001); and at least one late dose among the triplet series significantly less often than normal women (23% vs. 17%, p<0.001).


In a safety net population HPV4 vaccine adherence worsens as BMI increases.

Harper DM, Else BM, Bartley MJ, Arey AM, Barnett AL, Rosemergey BE, Paynter CA, Verdenius I, Harper SM, Harris GD, Groner JA, Malnar GJ, Wall J, Bonham AJ - PLoS ONE (2014)

Distribution of mistimed triplet HPV4 dosing by BMI category.Among women receiving three doses of HPV4, obese III women received at least one early dose among the triplet series significantly more often than normal women (25% vs. 13%, p<0.001); and at least one late dose among the triplet series significantly less often than normal women (23% vs. 17%, p<0.001).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4116139&req=5

pone-0103172-g002: Distribution of mistimed triplet HPV4 dosing by BMI category.Among women receiving three doses of HPV4, obese III women received at least one early dose among the triplet series significantly more often than normal women (25% vs. 13%, p<0.001); and at least one late dose among the triplet series significantly less often than normal women (23% vs. 17%, p<0.001).
Mentions: 64% of obese II/III women received three HPV4 doses on time with 36% mistiming at least one dose. Figure 2 shows that obese II/III women received at least one early or late dose equally often (22% vs. 16%, p>0.05), whereas normal BMI women received late doses more often than early doses (23% vs. 13%, p<0.5). Among women receiving three doses of HPV4, obese III women received at least one early dose among the triplet series significantly more often than normal women (25% vs. 13%, p<0.001); and at least one late dose among the triplet series significantly less often than normal women (23% vs. 17%, p<0.001).

Bottom Line: Females with normal BMI received on-time triplet dosing significantly more often than did the obese class II and III females (30% vs. 18%, p<0.001).Pregnancy history has a significant influence on BMI and HPV4 dosing compliance in this safety net population where 71% had been gravid.Obesity, as well as gravidity and Hispanic race, are risk factors for lack of HPV4 vaccine adherence among young females in a safety net population.

View Article: PubMed Central - PubMed

Affiliation: Department of Community and Family Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, United States of America; Department of Obstetrics and Gynecology, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, United States of America; Department of Biomedical and Health Informatics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, United States of America.

ABSTRACT

Objectives: Obesity adversely inhibits antibody response to vaccination. Three doses of HPV4 may or may not provide adequate long term protection against HPV 16/18 in obese females. The aim of this study was to determine whether adherence to HPV4 vaccination in a safety net population was reduced with increasing body mass index (BMI).

Methods: We designed a historical prospective study evaluating the number and dates of HPV4 dosing that occurred from July 1, 2006 through October 1, 2009 by the demographic characteristics of the 10-26 year old recipient females. The defined dosing intervals were adapted from the literature and obesity categories were defined by the WHO.

Results: 1240 females with BMI measurements received at least one dose of HPV4; 38% were obese (class I, II and III) and 25% were overweight. Females with normal BMI received on-time triplet dosing significantly more often than did the obese class II and III females (30% vs. 18%, p<0.001). Obese class II/III females have a significant 45% less chance of completing the on-time triplet HPV4 series than normal women (OR = 0.55, 95% CI: 0.37, 0.83). Pregnancy history has a significant influence on BMI and HPV4 dosing compliance in this safety net population where 71% had been gravid. Hispanic females were less likely to complete HPV4 dosing regardless of BMI (aOR = 0.39, 95% CI: 0.16, 0.95).

Conclusions: Obesity, as well as gravidity and Hispanic race, are risk factors for lack of HPV4 vaccine adherence among young females in a safety net population.

Show MeSH
Related in: MedlinePlus